CCDC88B

CCDC88B (HkRP3/Gipie) is a cytoskeleton-associated scaffold protein that governs immune cell migration and effector function while also modulating the ER stress response (PMID:25762780, PMID:25403443, PMID:21289099). In NK cells it binds microtubules, the dynein motor complex, and DOCK8, and its loss disrupts MTOC polarization and clustering of lytic granules, impairing cytotoxicity (PMID:25762780). Genetic loss-of-function in mice establishes CCDC88B as a regulator of T cell maturation, activation, proliferation, and cytokine production downstream of TCR engagement (PMID:25403443), and as a T cell-intrinsic driver of inflammatory colitis (PMID:29030607). In dendritic cells, CCDC88B is required for cell-intrinsic motility and migration to draining lymph nodes (PMID:32480428), acting through a complex with the RhoGEF ARHGEF2 and the RasGAP RASAL3 that controls RHOA activation, with the two partners exerting opposing effects (PMID:38200184). Separately, in endothelial and vascular smooth muscle cells, CCDC88B (Gipie) interacts with GRP78 to stabilize the GRP78-IRE1 complex at the ER, attenuating IRE1-driven JNK activation and protecting against ER stress-induced apoptosis (PMID:21289099, PMID:25792451).

1. 2011 High

   Established the first molecular function for the protein, showing Gipie acts at the ER to buffer the unfolded protein response rather than being an uncharacterized coiled-coil protein.

   Evidence Co-IP, siRNA knockdown, phospho-JNK and apoptosis assays in endothelial cells, plus rat carotid balloon injury model

   PMID:21289099

   Open questions at the time

   • Did not define the domain mediating GRP78 binding
   • Did not connect ER function to the protein's immune roles
2. 2014 High

   Placed CCDC88B in the immune system, demonstrating it is required for T cell maturation, activation, and cytokine output, defining a wholly distinct physiological context from its ER role.

   Evidence ENU mutagenesis screen, loss-of-function mouse model, flow cytometry, in vitro TCR stimulation, P. berghei infection

   PMID:25403443

   Open questions at the time

   • Molecular mechanism linking CCDC88B to TCR signaling not identified
   • No direct biochemical partners defined in T cells
3. 2015 High

   Provided a cytoskeletal mechanism in NK cells, showing the protein bridges microtubules, dynein, and DOCK8 to drive MTOC polarization and lytic granule clustering required for cytotoxicity.

   Evidence Subcellular fractionation, reciprocal Co-IP, siRNA knockdown with cytotoxicity and MTOC polarization assays

   PMID:25762780

   Open questions at the time

   • Did not resolve how the same protein operates at both the ER and the MTOC
   • Stoichiometry and direct vs indirect nature of dynein/DOCK8 binding not established
4. 2015 Medium

   Extended the ER stress-protective role to vascular smooth muscle cells, linking Gipie to JNK suppression, collagen maturation, and neointimal remodeling in vivo.

   Evidence siRNA knockdown, thapsigargin induction, phospho-JNK and apoptosis assays, rat carotid injury with adenoviral gain/loss of function

   PMID:25792451

   Open questions at the time

   • Largely extends the prior endothelial Gipie study without new molecular detail
   • Mechanistic link from IRE1-JNK to collagen I unresolved
5. 2017 High

   Demonstrated disease relevance by showing CCDC88B acts cell-intrinsically in CD4+ T cells to drive colitis, converting a cellular phenotype into a pathogenic axis.

   Evidence T cell transfer and DSS colitis models in Ccdc88b-deficient mice, histopathology, flow cytometry

   PMID:29030607

   Open questions at the time

   • Did not identify the signaling node within T cells responsible
   • Whether effect is migration-driven or activation-driven not dissected here
6. 2020 High

   Isolated migration as a core function by showing Ccdc88b-mutant dendritic cells have an intrinsic motility defect that prevents lymph node homing, independent of antigen presentation.

   Evidence In vivo LPS recruitment and OVA-DC immunization, time-lapse microscopy, contact hypersensitivity model in mutant mice

   PMID:32480428

   Open questions at the time

   • Molecular driver of the motility defect not yet identified at this stage
   • Cytoskeletal mechanism in DCs not directly visualized
7. 2024 High

   Provided the molecular machinery for DC migration, identifying a CCDC88B/ARHGEF2/RASAL3 complex that tunes RHOA activity with opposing GEF and GAP arms.

   Evidence AP-MS and Co-IP, in vitro DC migration and RHOA activation assays, Arhgef2 and Rasal3 mutant mouse models

   PMID:38200184

   Open questions at the time

   • How CCDC88B coordinates opposing ARHGEF2/RASAL3 activities mechanistically unclear
   • Spatial/temporal regulation of RHOA at the migrating cell front not resolved
8. 2023 Medium

   Implicated CCDC88B in tumor cell-mediated immune suppression, showing its silencing in adenoid cystic carcinoma cells unleashes NK and reduces regulatory T cell activity.

   Evidence siRNA silencing in 3D immune co-culture, flow cytometry for apoptosis, Tregs, and activated NK cells, granzyme/perforin assays

   PMID:37813936

   Open questions at the time

   • No molecular mechanism identified in the tumor context
   • Single specialized co-culture system without in vivo validation

• It remains unknown how a single scaffold reconciles its ER stress-buffering function with its cytoskeletal/RHOA-dependent roles in immune cell migration and effector function.
• No structural model mapping domains to GRP78 vs dynein/DOCK8 vs ARHGEF2/RASAL3 binding
• No demonstration of dimerization function in mammalian cells
• Context-dependent partner switching mechanism uncharacterized